CMS advises founders of AI start-up Semalytix on Series A financing round

Berlin – Bielefeld-based technology start-up Semalytix GmbH has raised EUR 4.3 million in its Series A round of financing. The firm offers pharmaceutical companies an AI-powered data tool for gaining a better understanding of real-world patient experiences. The round was led by btov Partners. The existing investor, Fly Ventures, as well as other unnamed angel investors joined the current round. The start-up will use the fresh capital for further development of its business with pharmaceutical companies and the wider healthcare market.

A CMS team headed by lead partner Dr Jörg Zätzsch advised the founders of Semalytix on all legal aspects of the financing and associated documentation.

Semalytix was established in 2015 as a spin-out of the Semantic Computing research group. It is a start-up for data and AI analytics that aims to bring more real-world evidence to the development of new drugs and treatments. Its flagship product, Pharos, is a patient research tool that captures a range of unstructured data streams in the public domain, such as blogs, forums, social media, etc. It extracts the relevant information, then applies algorithms to provide real-time insight into unmet needs, the experience of treatments and the impact of an illness on the lives of those affected.

CMS Germany

Dr Jörg Zätzsch, Lead Partner
Dr Friedrich von Spee, Senior Associate
Mario Galle, Associate
Martin Eichholz, Associate, all Corporate/Venture Capital
Dr Malte Grützmacher
Martin Kilgus, Senior Associate, both TMC
Dr Rolf Hempel, Partner, Competition

Press Contact
presse@cms-hs.com